Kai Wang, Yanrong Jiang, Xiaoxin Li
People Eye Centre of People's Hospital, No 11 South Avenue of XiZhiMen, XiCheng District, Beijing, People's Republic of China.
Graefes Arch Clin Exp Ophthalmol. 2006 Sep;244(9):1152-9. doi: 10.1007/s00417-005-0251-9. Epub 2006 Feb 2.
Intravitreal triamcinolone acetonide (TA) has been widely used as a therapeutic method for many ocular diseases, but a consensus on an appropriate safe therapeutic window of dosage for intravitreal injection, and whether vehicle of TA should be reduced or eliminated, has not yet been reached. The aim of this article is to investigate these issues.
Forty New Zealand white rabbits were divided into four experimental groups and one control group. Four or 25 mg TA, with vehicle either reduced or not, was injected into the vitreous cavity of rabbits in experimental groups. Rabbits in the control group received 0.2 ml intravitreal sterile saline solution. Intraocular pressures (IOP) were measured by a Tonopen tonometer. Values of lens density were measured by a Pentacam system. Soluble protein, total antioxidation capacity, reduced glutathione (GSH), glutathion peroxidase (GSH-px), and superoxide dismutase (SOD) in lens were measured by specific kits. ERG and pathological examinations, including light and electron microscopy of the retina, were also performed.
Elevation of IOP was noted in all experimental groups after intravitreal TA (P<0.01, paired t-test). Significant increase of lens density was noticed at 1 week after intravitreal TA in the 25 mg vehicle-containing group (P<0.0001, paired t-test). Significant loss of GSH-px activity was noticed at the end of the study (P<0.05, paired t-test), while SOD activity increased (P<0.05, paired t-test). Amplitudes of ERG waves declined significantly in vehicle-containing groups (P<0.01, paired t-test) at the end of the study. Pathological examination showed obvious retinal toxicity in vehicle-containing groups.
Vehicle of TA should be eliminated or reduced before intravitreal injection to avoid potential retinal toxicity and transient increase in lens density.
玻璃体内注射曲安奈德(TA)已被广泛用作多种眼部疾病的治疗方法,但对于玻璃体内注射合适的安全治疗剂量窗口以及TA的赋形剂是否应减少或去除,尚未达成共识。本文旨在研究这些问题。
将40只新西兰白兔分为四个实验组和一个对照组。在实验组中,将4毫克或25毫克TA(赋形剂减少或未减少)注入兔眼玻璃体腔。对照组的兔子接受0.2毫升玻璃体内无菌盐溶液。用非接触眼压计测量眼压。用Pentacam系统测量晶状体密度值。用特定试剂盒测量晶状体中的可溶性蛋白、总抗氧化能力、还原型谷胱甘肽(GSH)、谷胱甘肽过氧化物酶(GSH-px)和超氧化物歧化酶(SOD)。还进行了视网膜电图(ERG)和病理检查,包括视网膜的光镜和电镜检查。
玻璃体内注射TA后,所有实验组的眼压均升高(P<0.01,配对t检验)。在含25毫克赋形剂的组中,玻璃体内注射TA后1周晶状体密度显著增加(P<0.0001,配对t检验)。在研究结束时,GSH-px活性显著降低(P<0.05,配对t检验),而SOD活性增加(P<0.05,配对t检验)。在研究结束时,含赋形剂组的ERG波幅显著下降(P<0.01,配对t检验)。病理检查显示含赋形剂组有明显的视网膜毒性。
玻璃体内注射前应去除或减少TA的赋形剂,以避免潜在的视网膜毒性和晶状体密度的短暂增加。